Showing results (251-260 of 313) with videos related to
Sort By:
Pageof 32
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.Blood|February 15, 2007
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.Molecular Cancer|June 4, 2013
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cellsUri Rozovski, George A Calin, Tetsuro Setoyama, et al.Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureUri Rozovski, Ohad Benjamini, Preetesh Jain, et al.Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemiaFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.Journal of Hematology & Oncology|May 15, 2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndromeAzra Raza, Naomi Galili, Natalie Callander, et al.Cancer|September 3, 2011
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndromeAzra Raza, Naomi Galili, Scott E Smith, et al.Pageof 32